{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-22-000046","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.031056+00:00","generated_at":"2026-06-25T21:50:19.956336+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gossamer Bio Q1 net loss $57.8M ($0.76/diluted); TORREY enrollment complete; cash $271.6M","bullets":["Phase 2 TORREY study (seralutinib in PAH) completed enrollment; topline data expected Q4 2022.","Cash, cash equivalents & marketable securities: $271.6M as of March 31, 2022; runway into first half 2024.","Net loss of $57.8M ($0.76 per share) vs $57.6M ($0.78) in Q1 2021; R&D $42.3M, G&A $12.0M.","GB5121 Phase 1b/2 STAR CNS study in PCNSL expected to initiate Q2 2022.","GB7208 Phase 1 in neuroinflammatory diseases planned for H1 2023, pending TORREY results."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-22-000046","json":"https://secwatch.observer/filing/0001728117-22-000046.json","markdown":"https://secwatch.observer/filing/0001728117-22-000046.md","text":"https://secwatch.observer/filing/0001728117-22-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811722000046/0001728117-22-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811722000046/goss-20220510x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:50:19.956336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}